Overview / Abstract: |
STATEMENT OF NEED Multiple myeloma is a disease that remains incurable for most patients, many of whom become refractory to the majority of available treatments (Kumar et al, 2022). It is estimated that 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Agents targeting B-cell maturation antigen (BCMA), including antibody-drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell therapies, and bispecific T-cell engagers, represent a promising therapy class for patients in need of additional treatment options, including those with higher genetic risk and heterogeneity (Kumar et al, 2022). This activity led by Rahul Banerjee, MD, FACP, Assistant Professor in the Division of Medical Oncology at the University of Washington and Fred Hutchinson Cancer Center, will provide strategies for leveraging BCMA-directed therapies for improved patient outcomes in relapsed/refractory multiple myeloma. TARGET AUDIENCE Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with multiple myeloma (MM). LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: |
Expiration |
May 22, 2024 |
Discipline(s) |
Physician CME, Physician Assistant CME |
Format |
Online, Webinar / Webcast / Video |
Credits / Hours |
1.0 CME |
Accreditation |
ACCME, ANCC |
Presenters / Authors / Faculty |
Rahul Banerjee, MD, FACP |
Sponsors / Supporters / Grant Providers |
This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc. |
Keywords / Search Terms |
i3 Health Oncology, i3 Health, CME, NCPD, free CNE, free NCPD, Free CE, Free CME, MM, multiple myeloma, multiply relapsed, refractory, refractory multiple myeloma, therapeutics, treatment, therapies, patients, Free, CME, CE, hematologist, hematology, oncology, clinical data, therapy Free CE CME Free CE CME |